{"nctId":"NCT01276457","briefTitle":"Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients","startDateStruct":{"date":"2006-05"},"conditions":["Transplantation Infection"],"count":223,"armGroups":[{"label":"Upper everolimus blood target + very low dose cyclosporine","type":"EXPERIMENTAL","interventionNames":["Drug: Everolimus 0.25 and 0.75 mg tablets","Drug: Cyclosporine very low dose (150-300 ng/mL) microemulsion"]},{"label":"Standard everolimus blood target + low dose cyclosporine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Everolimus 0.25 and 0.75 mg tablets","Drug: Cyclosporine low dose (350-500 ng/mL) microemulsion"]}],"interventions":[{"name":"Everolimus 0.25 and 0.75 mg tablets","otherNames":[]},{"name":"Cyclosporine very low dose (150-300 ng/mL) microemulsion","otherNames":["Neoral"]},{"name":"Cyclosporine low dose (350-500 ng/mL) microemulsion","otherNames":["Neoral"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with functioning graft who had completed the 6-month treatment period of core study\n* Patients who were receiving treatment with either everolimus and cyclosporin at the end of the core study\n* Patients who signed the informed consent of the present study extension\n\nExclusion Criteria:\n\n\\- Women who were pregnant, lactating or who wished to became pregnant.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Biopsy-proven Acute Rejection","description":"A graft core biopsy was performed on all suspected acute rejection episodes within 48 hours. Biopsies were read by the local pathologist according to the 1997 Banff criteria. A biopsy-proven acute rejection was be defined as a biopsy graded IA, IB, IIA, IIB, or III.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"PRIMARY","title":"Renal Function Assessed by Creatinine Clearance","description":"Renal function was assessed by measuring serum creatinine and by computing creatinine clearance using the formula of Cockcroft-Gault.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.26","spread":"22.06"},{"groupId":"OG001","value":"62.50","spread":"20.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.90","spread":"22.85"},{"groupId":"OG001","value":"62.80","spread":"21.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.92","spread":"25.37"},{"groupId":"OG001","value":"63.76","spread":"21.71"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died, Number of Participants Who Lost Their Graft, and Number of Participants Who Died or Lost Their Graft","description":"A participant lost his graft if he/she started dialysis and was not able to subsequently be removed from dialysis or underwent graft nephrectomy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Deaths","description":"Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":85,"n":142},"commonTop":["Anaemia","Urinary tract infection","Dyslipidaemia","Oedema peripheral","Pyrexia"]}}}